Plain-English translation of NCT07194005 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications—disitamab vedotin, , and SOX—can shrink advanced stomach cancer tumors enough that they become safe to remove with surgery. The study focuses on patients whose tumors have specific HER2 markers and cannot currently be operated on. If the treatment works, surgery may then be possible to try to remove the remaining cancer.
Many patients with advanced stomach cancer cannot have surgery right away because their tumors are too large or have spread too far. Researchers hope that this medication combination can shrink these tumors first, making surgery possible and potentially improving survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug medication combination on a regular schedule, with imaging scans (like CT scans) every 6 to 12 weeks to see how well the treatment is working. If your tumor shrinks enough to meet surgery criteria, you would proceed to have an operation to remove the cancer. If surgery becomes possible, you may receive additional treatment after surgery based on your doctor's judgment. If the tumor does not shrink enough, your doctor will decide whether to continue the current treatment or try a different approach.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China